Get started
Author

Allison L Naumovski

Observed name: Allison Naumovski
ORCID: 0009-0007-3021-6135
Observed ORCID: 0009-0007-3021-6135
OpenAlex ID: A5025149042
RAGE Enhances TLR Responses through Binding and Internalization of RNA
2016 · Damien Bertheloot, Allison L Naumovski, et al. · The Journal of Immunology · 61
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
2024 · Ludimila Cavalcante, Sreenivasa Chandana, et al. · Journal for ImmunoTherapy of Cancer · 15
PDF
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
2024 · Diwakar Davar, Ludimila Cavalcante, et al. · Journal for ImmunoTherapy of Cancer · 9
Initial Report of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoimmune Cytopenias: The RUBY-4 Study
2023 · Catherine Broome, David J Kuter, et al. · Blood · 9
Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE).
2021 · Kyriakos P. Papadopoulos, Nehal J. Lakhani, et al. · Journal of Clinical Oncology · 4
Abstract 1727: Tumor associated macrophages and resistance to immune checkpoint blockade: consideration of cancer indications for the clinical development of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody
2021 · Lara McGrath, Amy Mueller, et al. · Cancer Research · 1
738 Interim dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in advanced malignancies (NEON-2)
2022 · Nehal Lakhani, Amita Patnaik, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 7
Citation count: 99
H-index: 4
I10-index: 2
Year
Topic
Type